Subscribe - Individual

Subscribe - Biotech Premium (Corporate)


November 3rd, 2023

Immuron Achieves Record Travelan Sales in September Quarter

Immuron (IMC: $0.075) has reported a record $1.5 million in sales in the September quarter for its Travelan product used to prevent travelers' diarrhea.

immuron 938
May 19th, 2023

Immuron Receives FDA Clearance for Third US Study

The FDA has removed a clinical hold on Immuron's (IMC: $0.08) study for a new therapeutic to prevent infectious diarrhea, caused by two bacteria, E. coli and Campylobacter.

May 1st, 2023

Immuron – Sales Start to Rebound Strongly

Immuron's (IMC: $0.078) business was severely impacted by the pandemic, with its lead product, Travelan, sold to prevent traveller's diarrhea. Sales fell from $2.7 million in FY2020 to just $166,000 in FY2021.